Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Press Release: Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
2025-03-13
The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable and accelerate the development of novel therapeutics.
Stockholm, Sweden, March 13, 2025 – Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets. This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases.
Collaboration and Licensing Agreement with Top Tier South Korean Pharma Company
2025-03-05
Salipro has entered into a collaboration and licensing agreement with one of the top tier pharmaceutical companies in South Korea.
This partnership leverages Salipro Biotech’s expertise and proprietary technology (Salipro®) to stabilise challenging drug targets including GPCRs, ion channels and transporters, making them accessible for the development of next-generation therapeutics.
Stay tuned for more updates as we continue to expand our global footprint in our mission to make the undruggable druggable!
Salipro to present at NextGen Biomed 2025
2025-03-03
Join us next week at NextGen Biomed 2025 in London, UK (March 12-14)!
Our Senior Scientist, Anne-Sophie Åstrand-Tournillon, will be there to present a poster on the latest advancements with the Salipro® platform for biologics targeting membrane protein drug targets.
This is a fantastic opportunity to connect with us. Be sure to stop by Anne-Sophie’s poster and say hello to her.
We look forward to connecting with you there!
Find more information on NextGen Biomed on their website: https://oxfordglobal.com/nextgen-biomed/events/nextgen-biomed